A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma
Oncology, 06/04/2012
Clinical Article
Stenner F et al. – The SoSu sequence translates into a longer combined progression–free survival (PFS) compared to the first–line sunitinib and 2nd–line sorafenib (SuSo) sequence. Predominantly the superiority of sunitinib regarding PFS2 contributed to the longer combined PFS in sequential use.



